|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10,794.00 GBX | -1.32% |
|
-0.26% | +3.11% |
| 02:05am | ASTRAZENECA : Goldman Sachs gives a Buy rating | ZD |
| Jan. 20 | Jefferies raises Spirax; Peel Hunt cuts Grainger | AN |
| Capitalization | 206B 198B 187B 167B 295B 17,747B 329B 2,271B 841B 7,322B 772B 756B 32,046B | P/E ratio 2024 * |
24.9x | P/E ratio 2025 * | 20.1x |
|---|---|---|---|---|---|
| Enterprise value | 228B 220B 207B 186B 327B 19,690B 365B 2,519B 934B 8,123B 857B 839B 35,555B | EV / Sales 2024 * |
4.29x | EV / Sales 2025 * | 3.91x |
| Free-Float |
96.62% | Yield 2024 * |
2.34% | Yield 2025 * | 2.48% |
More valuation ratios
* Estimated data
More news
Last Transcript: AstraZeneca PLC
More recommendations
More press releases
More news
| 1 day | -1.32% | ||
| 1 week | -0.26% | ||
| Current month | +3.11% | ||
| 1 month | +5.25% | ||
| 3 months | -9.64% | ||
| 6 months | -10.84% | ||
| Current year | +3.11% |
1 week
10 577.48
11 122.00
1 month
10 304.0011 122.00
Current year
10 314.0011 122.00
1 year
9 461.0013 388.00
3 years
8 214.0013 388.00
5 years
5 871.0013 388.00
10 years
3 680.0013 388.00
| Director | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 64 | 2012-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 51 | 2021-07-31 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 57 | 2019-12-31 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 69 | 1999-04-05 | |
Pascal Soriot
BRD | Director/Board Member | 64 | 2012-09-30 |
Philip Broadley
BRD | Director/Board Member | 64 | 2017-04-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.20% | 0 M€ | +0.83% | - | |
| 8.29% | 57 M€ | +0.79% | - | |
| 5.39% | 209 M€ | +1.76% | ||
| 5.17% | 30 M€ | +1.14% | - | |
| 4.89% | 568 M€ | +6.06% |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -1.32% | -0.26% | +2.72% | +22.08% | 206B | ||
| -4.21% | -9.00% | +15.45% | +198.49% | 653B | ||
| -0.50% | +1.77% | -9.06% | -11.03% | 354B | ||
| -4.22% | -10.08% | -24.73% | +73.23% | 341B | ||
| -1.23% | -2.93% | +4.12% | +28.96% | 303B | ||
| -2.76% | -3.03% | -17.64% | +21.26% | 248B | ||
| +0.57% | +0.76% | +9.34% | -26.90% | 236B | ||
| -0.10% | -1.72% | -4.87% | +9.63% | 197B | ||
| -0.72% | -1.87% | -7.00% | -51.34% | 149B | ||
| +0.99% | +0.71% | -11.60% | +18.88% | 146B | ||
| Average | -1.35% | -1.83% | -4.33% | +28.33% | 283.38B | |
| Weighted average by Cap. | -1.96% | -3.21% | -1.98% | +56.47% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 53.3B 51.25B 48.39B 43.33B 76.32B 4,595B 85.12B 588B 218B 1,896B 200B 196B 8,298B | 56.94B 54.75B 51.69B 46.29B 81.52B 4,908B 90.92B 628B 233B 2,025B 214B 209B 8,863B |
| Net income | 8.19B 7.87B 7.43B 6.66B 11.72B 706B 13.07B 90.31B 33.47B 291B 30.71B 30.07B 1,275B | 10.33B 9.93B 9.38B 8.4B 14.79B 891B 16.5B 114B 42.23B 367B 38.75B 37.95B 1,608B |
| Net Debt | 22.54B 21.68B 20.46B 18.33B 32.28B 1,943B 36B 249B 92.14B 802B 84.54B 82.8B 3,509B | 16.55B 15.91B 15.02B 13.46B 23.7B 1,427B 26.43B 183B 67.65B 589B 62.07B 60.79B 2,576B |
More financial data
* Estimated data
Employees
89,900
Sector
Pharmaceuticals
Calendar
2025-02-06
- Q4 2024 Earnings Release
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-01-20 | 10,794.00 p | -1.32% | 1,013,433 |
| 25-01-17 | 10,938.00 p | +0.87% | 2,895,289 |
| 25-01-16 | 10,844.00 p | +1.84% | 1,140,265 |
| 25-01-15 | 10,648.00 p | +0.17% | 1,861,443 |
| 25-01-14 | 10,630.00 p | -1.77% | 3,903,004 |
Delayed Quote London S.E., January 20, 2025 at 11:35 am EST
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
132.77USD
Average target price
172.06USD
Spread / Average Target
+29.60%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AZN Stock
